Medical Coverage Policy

Repetitive Transcranial Magnetic Stimulation (TMS) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders-PREAUTH

☐ Device/Equipment  ☐ Drug  ☐ Medical  ☒ Surgery  ☐ Test  ☐ Other

Effective Date: 3/17/2012  Policy Last Updated: 6/18/2013

☒ Prospective review is recommended/required. Please check the member agreement for preauthorization guidelines.

☐ Prospective review is not required.

Description:
Transcranial magnetic stimulation (TMS also called repetitive transcranial magnetic stimulation [rTMS]) is a non-invasive method of delivering electrical stimulation to the brain. A magnetic field is delivered through the skull where it induces electric currents that affect neuronal function. Repetitive TMS is being evaluated as a treatment of depression and other psychiatric/neurologic brain disorders.

rTranscranial magnetic stimulation was first introduced in 1985 as a new method of non-invasive stimulation of the brain. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. rTMS was initially used to investigate nerve conduction; for example, rTMS over the motor cortex will produce a contralateral muscular-evoked potential. The motor threshold, which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each individual by localizing the site on the scalp for optimal stimulation of a hand muscle, then gradually increasing the intensity of stimulation. The stimulation site for treatment is usually 5 cm anterior to the motor stimulation site.

rTMS is also being tested as a treatment for a variety of other disorders including alcohol dependence, Alzheimer’s disease, neuropathic pain, obsessive-compulsive disorder (OCD), postpartum depression, depression associated with Parkinson’s disease, Tourette’s syndrome, schizophrenia, migraine, spinal cord injury, fibromyalgia, and tinnitus.

According to Centers for Medicare and Medicaid Services, when used as an antidepressant therapy, rTMS may produce a clinical benefit without the systemic side effects typical with oral medications, has no adverse effects on cognition, and unlike electroconvulsant therapy does not induce amnesia or seizures. rTMS offers a well-tolerated, non-pharmacologic alternative
that does not require attendant anesthesia services and can be administered in an outpatient setting for patients with DSM-IV defined Major Depressive Disorder who have failed to benefit from initial treatment of their depression. When effective, rTMS may prevent the need to utilize more complex pharmaceutical augmentation strategies (e.g., atypical antipsychotic medication), electroconvulsive therapy (ECT), and inpatient hospitalization at later stages of the illness. The use of rTMS as a maintenance therapy is not supported by controlled clinical trial at this time and is therefore, considered not reasonable and necessary.

**Cautionary Uses**

The benefits of rTMS use must be carefully considered against the risk of potential side effects in patients with any of the following:

- Seizure disorder or any history of seizure (except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrence).
- The presence of vagus nerve stimulator leads in the carotid sheath.
- The presence of an implanted medical device located > 30 cm from the rTMS magnetic coil, including but not limited to pacemakers, implanted defibrillators, or vagus nerve stimulators.

The use rTMS is typically recommended for up to 30 visits over a 7-week period followed by 6 taper treatments.

**Medical Criteria:**

**All BCBSRI Products**

Left prefrontal rTMS is covered for patients diagnosed with severe major depression (single or recurrent episode) as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), who also have at least one of the following:

- Resistance to treatment with psychopharmacologic agents as evidenced by a lack of clinically significant response to four trials of such agents, in the current depressive episode, from at least two different agent classes. At least one of the treatment trials must have been administered at an adequate course of mono- or poly–drug therapy; or
- Inability to tolerate psychopharmacologic agents as evidenced by trials of four such agents with distinct side effects; or
- History of good response to rTMS in a previous episode; or
- If patient is currently receiving electroconvulsive therapy, rTMS may be considered reasonable and necessary as a less invasive treatment option.

Repeat acute treatment for relapse of depressive symptoms is considered medically necessary if the patient responded to prior treatments, specifically > 50% improvement in a standard rating scale for depressive symptoms (e.g., (GDS), PHQ-9, BDI, HAM-D, MADRS, QIDS or IDS-SR score). If patient meets the relapse criteria, up to 30 visits for the acute phase treatment followed by an additional 6 visits for tapering is considered reasonable and necessary.

rTMS should not be used in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head which are non-removable and within 30cm of the rTMS
magnetic coil. Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coil, stents, and bullet fragments. Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with rTMS.

Policy:
Preauthorization is required for BlueCHiP for Medicare and recommended for all other BCBSRI products.

Repetitive transcranial magnetic stimulation is covered for all BCBSRI products as a treatment of depression and other psychiatric/neurologic disorders when the criteria above is met.

rTMS is considered not medically necessary when used as a treatment modality for patients with any of the following:
- Presence of psychotic symptoms in current depressive episode.
- Chronic or acute psychotic disorder such as schizophrenia, schizophreniform disorder, or schizoaffective disorder.

Coverage:
Benefits may vary between groups/contracts. Please refer to the Evidence of Coverage, Subscriber Agreement or Benefit Booklet for applicable outpatient hospital services benefits.

Coding:
The following codes are covered for all BCBSRI products with preauthorization:
90867
90868
90869

Also known as:
TMS
rTMS

Related topics:
None

Published:
Provider Update, August 2013
Provider Update, July 2012
Provider Update, May 2012
Provider Update, February 2011
Provider Update, October 2010
Provider Update, August 2009
References:
Blue Cross and Blue Shield Association Medical Policy Reference Manual. 2.01.50 Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders.

Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcranial magnetic stimulation for depression. TEC Assessments 2009; Volume 24, Tab 5.

Centers for Medicare and Medicaid Services. Local Coverage Determination (LCD) for Repetitive Transcranial Magnetic Stimulation (rTMS) (LCD32228)

Review History:
06/18/2013: Annual review added Medicare coverage rationale.

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice.